We report that transfection of IGFBP-3 cDNA in human breast cancer cell lines expressing either mutant p53 (T47D) or wild-type p53 (MCF-7) induces apoptosis. IGFBP-3 also increases the ratio of proapoptotic to anti-apoptotic members of the Bcl-2 family. In MCF-7, an increase in Bad and Bax protein expression and decrease in Bcl-x L protein and Bcl-2 protein and mRNA was observed. In T47D, Bax and Bad proteins were upregulated; Bcl-2 protein is undetectable in these cells. As T47D express mutant p53 protein, these modulations of proapoptotic proteins and induction of apoptosis are independent of p53.
conditions these levels of exogenous IGFBP-3 may induce apoptosis indirectly by sequestering antiapoptotic IGFs from the IGFRI (12) . However, no induction of apoptosis was observed in either Hs578T breast carcinoma cells or colorectal carcinoma cells exposed to exogenous IGFBP-3 alone (0.1 -0.5 µg/ml; 13, 14) , although in both studies IGFBP-3 augmented the cellular response to apoptotic stimuli.
Studies by Rajah et al. in prostate carcinoma cells and IGFRI-negative mouse fibroblasts showed an induction of apoptosis by both exogenous and endogenous IGFBP-3 (15) and provide the strongest evidence of an IGFRI-independent pro-apoptotic role for IGFBP-3 in cancer cell growth.
IGFBP-3 gene expression is induced by potent growth inhibitory and pro-apoptotic agents including transforming growth factor β1 (TGFβ1; 16, 17) , retinoic acid (18) and tumor necrosis factor-α (19) with evidence that these agents may mediate their cellular effects through IGFBP-3. Furthermore, IGFBP-3 is an established target of the tumor suppressor p53 (20) . The latter plays a critical role in effecting the cellular response to IR, mediating both a G1 cell cycle arrest and induction of apoptotic cell death (21) , although which, if any of these cellular functions involve IGFBP-3 is less clear. In addition, the intracellular mechanisms by which IGFBP-3 mediates its IGFRI-independent antiproliferative and proapoptotic effects remain largely unknown. However, we have demonstrated that IGFBP-3 is translocated to the nucleus in breast carcinoma cells (22) raising the possibility that IGFBP-3 may mediate its cellular effects via direct or indirect interaction with growth-inhibitory and/or apoptotic genes.
The Bcl-2 family has been identified as an important regulator of mammalian cell death with both antiapoptotic (eg. Bcl-2, Bcl-x L ) and pro-apoptotic (eg. Bax, Bad) members (23) . Members of this family regulate susceptibility to apoptosis, whereby overexpression of Bcl-2 or Bcl-x L in relation to Bax promotes survival, but overexpression of Bax accelerates cell death (24) . Bax overexpression in MCF-7 breast cancer cells enhances radiation-induced apoptosis (25) , suggesting changes in the ratio of Bcl-2-related proteins may be an important determinant in the response of breast cancer cells to apoptotic stimuli.
In this study, the effect of IGFBP-3 on the induction of apoptosis in human breast cancer cells expressing either mutant p53 (T47D) or wild-type p53 (MCF-7) protein was examined. We demonstrate that IGFBP-3 induces apoptosis and modulates expression of Bcl-2-related proteins in a p53-independent manner. We also determined the ability of IGFBP-3 to restore the sensitivity of mutant p53-expressing breast cancer cells to the apoptotic effects of IR. Expression of IGFBP-3 increased T47D sensitivity to IR-induced apoptosis, without altering the cell cycle response. IR also caused a much greater increase in Bax protein in IGFBP-3-transfectants compared to vector controls. These results suggest that IGFBP-3 may be an important effector of apoptosis in breast cancer cells whether initiated by p53 or by other inhibitory agents, via its modulation of Bcl-2-related proteins.
EXPERIMENTAL PROCEDURES
Cell culture and transfection of breast cancer cells. The breast cancer cell lines T47D and MCF-7 were obtained from the American Type Culture Collection and were routinely maintained in RPMI-1640 supplemented with 10% FCS. T47D and MCF-7 cells were stably transfected with a 0.9kb IGFBP-3 cDNA fragment in the expression vector pOP13 (Invitrogen Corp., Carlsbad, CA) as described previously (6) . Cells were stably transfected using Lipofectamine (Life Technologies, Gaithersberg, MD) according to the manufacturer's protocol. IGFBP-3-transfectants and vector controls were selected in media containing either 400 µg/ml (T47D) or 800 µg/ml (MCF-7) of geneticin for 21 days post-transfection, then mixed populations of transfectants were grown up for subsequent experiments.
Analysis of conditioned media. Concentrations of IGFBP-3 in conditioned media from T47D transfectants were quantitated by radioimmunoassay (RIA) essentially as previously described (26) . Cells were seeded at 5x10 5 per well in 6-well plates for 24 hours then washed with fresh serum-free media.
Conditioned media were collected 24 hours later and analyzed for IGFBP-3. Levels of IGFBP-3 were also determined in transfectants 24 hours post-irradiation with 10 Gy X-rays. To determine if proteolysis of IGFBP-3 occurred following IR, conditioned media from unirradiated and irradiated transfectants were concentrated forty-fold and subjected to immunoblot analysis as previously described (27) .
Analysis of cell-surface associated IGFBP-3. Levels of IGFBP-3 associated with the cell surface were analyzed essentially as previously described (16) 24 hours post-irradiation with 10 Gy X-rays and in unirradiated controls.
Clonogenic survival assays.
The long-term survival of T47D transfectants following doses of irradiation was assessed by a clonogenic survival assay. 2 x 10 3 cells were seeded into 6-well plates in triplicate for 24 hours. Cells were then washed with fresh media and irradiated with various doses of X-rays (2.5, 5 or 7.5 Gy), then incubated for 14 days. At this time, cells were counted and the percentage survival determined by the proportion of attached cells surviving (assessed by trypan blue exclusion) relative to unirradiated controls.
Analysis of cell cycle distribution. Cells were plated at 5x10 5 per well in 6-well plates for 24 hours. Cells were then washed with fresh media and irradiated with 10 Gy X-rays. 24 hours post-irradiation, cells were trypsinized and aliquots of 1x10 6 cells were suspended in 1ml of fluorochrome solution (50 µg/ml propidium iodide, 1mg/ml RNase A, 1.5% Triton-X 100) for at least 1 hour in the dark at 4°C. Cell cycle analysis was performed using a Coulter ELITE flow cytometer (Coulter, Hialeah, FL). 20,000 cells were analyzed for each sample, and quantitation of cell cycle distribution was performed using Multicycle software (Phoenix Flow Systems, San Diego, CA). Northern analysis. RNA extraction and Northern analysis were performed essentially as previously described (28) . Bax cDNA probe was kindly provided by Dr. G. Packham, (Birmingham, UK) and labelled using a Ready-to-Go random priming kit (Pharmacia Biotech Inc., Uppsala, Sweden) and [α-32 P]deoxy-CTP. Filters were hybridized at 42°C overnight, then washed in 0.1 x SSC (standard saline citrate) at 42°C, with an additional wash in 1 x SSC if required. The ribosomal phosphoprotein, 36B4 was used as a loading control (29) . Filters were quantitated using a PhosphorImager (Molecular Dynamics, Sunnyvale, CA). Data were normalized by expressing the ratio of Bax mRNA to 36B4 mRNA, and expressed as a percentage of the vector control levels.
RT-PCR.
RT-PCR was used to quantitate Bcl-2 mRNA expression levels in T47D and MCF-7. Total RNA was extracted as described above, and 2.5µg was used in a first strand complementary DNA synthesis with 50µM oligo [dT] 17 . The forward and reverse primer sequences for human Bcl-2 were 5'-GTTCGGTGGGGTCATGTGTGTGGAGAGCG and 5'-TAGCTGATTCGACGTTTTGCCTGA, respectively. PCR was performed with [α-33 P]deoxy-CTP. The amplified PCR product was 466 bp.
Human actin primers were used as an internal standard. PCR products were size-fractionated through a 10% acrylamide gel, and the bands quantitated using a PhosphorImager.
Statistical analysis. Statistical analysis was carried out using StatView 4.02 (Abacus Concepts Inc., Berkeley, CA). Differences between groups of data were evaluated by Fisher's PLSD (Protected Least Significant Difference) test after analysis of variance. P < 0.05 was considered significant.
RESULTS

Stable transfection of IGFBP-3 cDNA in human breast cancer cells induces apoptosis.
We examined the effects of increased IGFBP-3 expression in T47D on the induction of apoptosis using three independent methods. The fragmentation of DNA characteristic of apoptosis results in a hypodiploid DNA content that can be visualised as a pre-G1 peak on a DNA cell cycle histogram. We used TUNEL analysis as a third quantitative method of determining apoptosis (Fig. 1E ). 
001). Levels of anti-apoptotic
Bcl-x L protein were not significantly altered in T47D/BP-3 compared to vector controls. As previously demonstrated by others (30) . we observed that T47D do not express detectable levels of Bcl-2 protein.
We then examined the effects of IGFBP-3 on Bax, Bad, Bcl-2 and Bcl-x L expression in the breast cancer cell line MCF-7 which expresses functionally wild-type p53 protein (30) . Similar to that seen in T47D cells, we observed a significant induction of Bax and Bad protein expression (p < 0.05, p < 0.001, respectively) in MCF-7 cells expressing IGFBP-3 compared to vector controls (Fig. 2 , Table 1 ).
Furthermore, examination of Bcl-2 and Bcl-x L proteins (Fig. 2) showed a significant decrease in expression in IGFBP-3-transfectants compared to controls (Table 1 , p < 0.05).
Both Bcl-2 and Bad proteins have been demonstrated to be functionally regulated by phosphorylation on serine residues. We examined the effects of IGFBP-3 expression on the phosphorylation status of these proteins. The Bcl-2 monoclonal antibody used in these experiments detects the p30 phosphorylated form of Bcl-2 protein (31). We did not detect any p30 phosphorylated Bcl-2 protein in either MCF-7/VEC or MCF-7/BP-3 by Western blotting with the Bcl-2 antibody (Fig. 2) . Furthermore, no higher molecular weight forms (approximately 25kDa; 32) of Bad protein were detected in either T47D or MCF-7 (Fig. 2) .
IGFBP-3 modulates the levels of bcl-2 mRNA but not bax mRNA. Wild-type p53 has been shown to transcriptionally modulate bcl-2 and bax (33, 34) with evidence that this may be a mechanism for its proapoptotic effects. We investigated the effects of IGFBP-3 expression on the mRNA levels of bax and bcl-2 in both T47D and MCF-7. Northern blot analysis was performed to determine the steady-state levels of bax mRNA in IGFBP-3-transfected cells and vector controls. As shown in Fig. 3A , the relative levels of both the major (1 kb) and minor (1.5 kb) bax mRNA transcripts were unchanged in IGFBP-3-transfectants compared with vector controls when normalized with the loading control, 36B4 ( Fig. 3A ; p > 0.05).
RT-PCR was used to quantitate bcl-2 expression levels in IGFBP-3-transfected cells compared to vector controls. Bcl-2 mRNA was not detected in T47D cells (Fig. 3B ). An approximately 75 percent decrease in bcl-2 mRNA was observed in MCF-7/BP-3 compared to vector controls when normalized with the loading control, actin ( Fig. 3B ; p < 0.05).
In summary, IGFBP-3 modulated expression of Bax protein without stimulating an increase in bax mRNA. However, expression of IGFBP-3 induced a significant (p < 0.05) decrease in bcl-2 mRNA levels in MCF-7 compared to vector controls.
Increased expression and secretion of IGFBP-3 by IGFBP-3-transfected T47D cells is not altered by
exposure to IR. T47D express mutant p53 protein (30) and are relatively resistant to radiation-induced apoptosis and do not exhibit a G1 arrest post-irradiation (35) . We used T47D to examine the effects of IGFBP-3 expression on the response of cells to radiation.
IGFBP-3-specific RIA of culture medium conditioned by T47D/BP-3 showed these cells secrete IGFBP-3, and levels of secretion were not altered by IR (Fig. 4A) , nor was there any change in the levels of cell-associated IGFBP-3 following IR (Fig. 4B) . Analysis of conditioned media from T47D/VEC confirmed our earlier findings (6) that these cells do not express detectable levels of IGFBP-3 (data not shown).
To determine if proteolysis of IGFBP-3 occurred following IR, conditioned media from unirradiated and irradiated transfectants were concentrated forty-fold and subjected to immunoblot analysis. The immunoreactive IGFBP-3 produced by both unirradiated and irradiated IGFBP-3-transfected cells appeared as a 40-45 kDa doublet species similar in size to recombinant human IGFBP-3 (Fig. 4C ). These results demonstrate that the expression and secretion of intact IGFBP-3 by T47D/BP-3 is not altered by exposure to IR.
IGFBP-3 increases the radiosensitivity of T47D. Radiosensitivity of T47D/BP-3 and T47D/VEC was evaluated using clonogenic survival assays which measure long-term survival post-irradiation. At doses of 2.5 and 5 Gy X-rays, IGFBP-3-expressing cells showed significantly reduced long-term (up to 14 days) survival (approx. 40% and 60% reduction respectively; p < 0.01) compared to vector controls ( Fig.   5 ). At the higher dose of 7.5 Gy, the surviving fraction was low in both T47D/BP-3 and T47D/VEC.
Expression of IGFBP-3 does not alter cell cycle distribution following IR.
To examine the effects of IGFBP-3 on the short-term (up to 48 hours) response of cells to radiation-induced G1 arrest and apoptosis as outlined below, the higher dose of 10 Gy X-rays was used.
T47D normally exhibit a G2/M arrest following exposure to IR (35) . To determine whether expression of IGFBP-3 restored a G1 arrest post-irradiation in these cells, the cell cycle distribution of both T47D/BP-3 and T47D/VEC was analyzed 24 hours following irradiation with 10 Gy X-rays and compared to unirradiated controls. There was no significant difference in the distribution of the two cell populations through the cell cycle, in either unirradiated or irradiated cells (Table 2 ; p > 0.5). We have previously
shown that expression of IGFBP-3 in T47D can elicit an accumulation of cells in G1 phase with a concomitant decrease of cells in S and G2/M phases (6). However, this accumulation of IGFBP-3-transfected cells in G1 was observed seven days post-seeding, with no changes in cell cycle distribution or evidence of G1 arrest observed at earlier time points (unpublished data) consistent with our results in this present study.
IGFBP-3 potentiates radiation-induced apoptosis in T47D.
We examined whether the reduction in longterm survival of IGFBP-3-transfectants post-irradiation was due to an increased rate of apoptosis. In addition, we analyzed changes in nuclear morphology indicative of apoptosis in the two cell populations post-irradiation. Cells were stained with the cell permeable DNA dye DAPI and scored for the presence of nuclear fragmentation (Fig. 6C ). There was a significant increase in the percentage of apoptotic cells in the IGFBP-3-expressing cells post-irradiation compared to unirradiated cells shown in Fig. 1D (p < 0.001), which was not observed post-irradiation in the vector control population. Altogether, the data showed that there were significantly more apoptotic cells in the IGFBP-3-expressing population following exposure to radiation compared to vector controls.
IGFBP-3 alters levels of Bax protein but not mRNA following irradiation. We examined the levels of
Bax, Bad and Bcl-x L proteins 48 hours following irradiation with 10 Gy X-rays. There was a significant increase in Bax protein levels (2.4 fold) following irradiation in T47D/BP-3 ( 
DISCUSSION
There is now accumulating evidence that IGFBP-3 has an important antiproliferative and pro-apoptotic role in the regulation of cancer cell growth (6). However, although it has been desscribed as an IGFindependent pro-apoptotic agent, there are still conflicting data to support this role for IGFBP-3. This 
